LY2886721

N.º de catálogoS2156 Lote:S215603

Imprimir

Datos técnicos

Fórmula

C₁₈H₁₆F₂N₄O₂S

Peso molecular

390.41

Número CAS

1262036-50-9

Solubilidad (25°C)*

In vitro

DMSO

35 mg/mL (89.64 mM)

Water

Insoluble

Ethanol

Insoluble

In vivo (Agregue los solventes al producto individualmente y en orden.)

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml significa ligeramente soluble o insoluble.
* Tenga en cuenta que Selleck prueba la solubilidad de todos los compuestos internamente, y la solubilidad real puede diferir ligeramente de los valores publicados. Esto es normal y se debe a ligeras variaciones entre lotes.
* Envío a temperatura ambiente (Las pruebas de estabilidad demuestran que este producto se puede enviar sin medidas de refrigeración.)

Preparación de soluciones madre

Actividad biológica

Descripción

LY2886721 es un inhibidor de BACE utilizado para el tratamiento de la enfermedad de Alzheimer. Fase 1/2.

Objetivos

BACE2 (Cell-free assay)	BACE1 (Cell-free assay)
10.2 nM	20.3 nM

In vitro

LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the clinical progression of AD. This compound can also targetγ-secretase to nhibit the synthesis of β-amyloid. It inhibits recombinant hBACE1 with an IC50 of 20.3 nM. In cellular assays, this chemical inhibits Abeta with an IC50 of 18.7 nM and 10.7 nM, HEK293Swe and PDAPP neuronal culture, respectively. It has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclinical animal models. Assessment of its activity against hBACE2 demonstrates an IC50 of 10.2 nM. Assessment of the compound's activity against cathepsin D, pepsin, renin, or other important aspartyl proteases shows essentially no inhibition (IC50 >100,000 nM), suggesting that activity against these common aspartyl proteases is unlikely to be significant.

In vivo

Oral administration of LY2886721 to PDAPP mice produces dose-dependent reductions in brain Abeta, C99 and sAPPbeta. Brain Abeta levels are decreased ∼20%-65% relative to vehicle-treated groups three hours after a 3-30 mg/kg dose of this compound. Brain C99 and sAPPb levels also are reduced in a dose-dependent manner consistent with BACE1 inhibition in vivo. The pharmacodynamic responses to this chemical persists out to 9 hours post dose in brains of PDAPP mice. Pharmacodynamic studies in beagle dog reveal robust and sustained reductions in plasma Abeta following 1 mg/kg dosing. Central effects of BACE1 inhibition in dog are manifested by a 50% reduction in CSF Abeta at 9 hours after a 0.5 mg/kg dose. The geometric mean terminal elimination t1/2 is determined to be 17.2 h (range 8.19-36.3 h). The geometric mean apparent oral clearance is 34.8 L/h (38% CV) and the apparent volume of distribution during the terminal phase was 863 L (56% CV) across dose levels. This compound is freely permeable across the blood-brain barrier.

Protocolo (de referencia)

Ensayo celular:^{^[4]}	Líneas celulares HEK293 cells Concentraciones -- Tiempo de incubación Overnight exposure Método A human embryonic kidney cell line (HEK293) stably expressing APP751cDNA containing a Swedish mutation (HEK293Swe) was exposed to increasing concentrations of LY2886721 and the amount of amyloid β1–40 (Aβ1-40) and Aβ1-42 measured in the media as an index of BACE1 inhibition. Compound cytotoxicity was assessed using a CellTiter96 Aqueous Non-Radioactive Cell Proliferation assay
Estudio en animales:^{^[4]}	Modelos animales young PDAPP transgenic mice Dosificaciones 1.5 mg/kg Administración by oral gavage

Ensayo celular:^{^[4]}

Líneas celulares
HEK293 cells
Concentraciones
--
Tiempo de incubación
Overnight exposure
Método
A human embryonic kidney cell line (HEK293) stably expressing APP751cDNA containing a Swedish mutation (HEK293Swe) was exposed to increasing concentrations of LY2886721 and the amount of amyloid β1–40 (Aβ1-40) and Aβ1-42 measured in the media as an index of BACE1 inhibition. Compound cytotoxicity was assessed using a CellTiter96 Aqueous Non-Radioactive Cell Proliferation assay

Estudio en animales:^{^[4]}

Modelos animales
young PDAPP transgenic mice
Dosificaciones
1.5 mg/kg
Administración
by oral gavage

Referencias

http://www.alz.org/ct/documents/adru_studies_2012_04_01.pdf
https://pubmed.ncbi.nlm.nih.gov/21368375/
http://www.alzheimersanddementia.com/article/S1552-5260(12)00367-6/abstract

https://pubmed.ncbi.nlm.nih.gov/25609634/

Expandir

Validación de productos por parte del cliente

: Datos de [ , , Cell Discov, 2015, 1:15021. ]

Selleck's LY2886721 Ha sido citado por 23 Publicaciones

Traumatic brain injury causes early aggregation of beta-amyloid peptides and NOTCH3 reduction in vascular smooth muscle cells of leptomeningeal arteries [ Acta Neuropathol, 2025, 149(1):10]	PubMed: 39841284
Inhibition of Amyloid β Accumulation by Protease-Digested Whitebait (Shirasu) in a Murine Model of Alzheimer's Disease [ Foods, 2024, 13(18)2858]	PubMed: 39335787
Familial Alzheimer's disease-associated PSEN1 mutations affect neurodevelopment through increased Notch signaling [ Stem Cell Reports, 2023, 18(7):1516-1533]	PubMed: 37352850
Beta-Site Amyloid Precursor Protein-Cleaving Enzyme Inhibition Partly Restores Sevoflurane-Induced Deficits on Synaptic Plasticity and Spine Loss [ Int J Mol Sci, 2022, 23(12)6637]	PubMed: 35743082
Beta-Site Amyloid Precursor Protein-Cleaving Enzyme Inhibition Partly Restores Sevoflurane-Induced Deficits on Synaptic Plasticity and Spine Loss [ International Journal of Molecular Sciences, 2022, 6637]	PubMed: 35743082
Aberrant role of pyruvate kinase M2 in the regulation of gamma-secretase and memory deficits in Alzheimer's disease [ Cell Rep, 2021, 37(10):110102]	PubMed: 34879266
ST6GAL1 and α2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease [ Front Immunol, 2021, 12:693149]	PubMed: 34290711
ST6GAL1 and α2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease [ Frontiers in Immunology, 2021, 693149]	PubMed: 34290711
Pathological methamphetamine exposure triggers the accumulation of neuropathic protein amyloid-β by inhibiting UCHL1 [ Neurotoxicology, 2021, 86:19-25]	PubMed: 34175320
Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain [ Mol Psychiatry, 2020, 10.1038/s41380-020-0806-5]	PubMed: 32647257

POLÍTICA DE DEVOLUCIÓN
La Política de Devolución Incondicional de Selleck Chemical garantiza una experiencia de compra en línea fluida para nuestros clientes. Si no está satisfecho con su compra de alguna manera, puede devolver cualquier artículo(s) dentro de los 7 días posteriores a su recepción. En caso de problemas de calidad del producto, ya sean problemas relacionados con el protocolo o con el producto, puede devolver cualquier artículo(s) dentro de los 365 días a partir de la fecha de compra original. Siga las instrucciones a continuación al devolver productos.

ENVÍO Y ALMACENAMIENTO
Los productos Selleck se transportan a temperatura ambiente. Si recibe el producto a temperatura ambiente, tenga la seguridad de que el Departamento de Inspección de Calidad de Selleck ha realizado experimentos para verificar que la colocación a temperatura normal durante un mes no afectará la actividad biológica de los productos en polvo. Después de la recogida, guarde el producto de acuerdo con los requisitos descritos en la hoja de datos. La mayoría de los productos Selleck son estables en las condiciones recomendadas.

NO PARA USO HUMANO, DIAGNÓSTICO VETERINARIO O TERAPÉUTICO.